Champions Oncology competitors

PHARMACEUTICAL EXECUTIVE WITH GLOBAL IMPACTIncreasing stakeholder value and meeting the needs of patients around the world.For over 25 years, I have increased profits and expanded market share for organizations in the pharmaceutical industry-from “big pharma” corporations to small biotech firms. Starting out in sales, I advanced over time to President of Bayer’s U.S. Pharmaceuticals organization. I currently serve as President and CEO of Acceleron Pharma, a public company.My work as an operations and commercial executive spans geographical regions, drug classes (small molecules, biologics), and therapeutic areas, including cardiovascular disease, hematology, neurology, neuromuscular, oncology, ophthalmology, pulmonary, and women’s health. Year after year, my teams have broken new ground by launching blockbuster brands, penetrating new markets, and outperforming sales expectations in competitive regions. Career Highlights:● Propelled Acceleron to a new stage of growth and shareholder value by pivoting the formerly research-focused company toward innovation and pre-commercialization. Increased stock performance vs the biotech index in 2017 & 2018, and positioned the company to potentially launch its first blockbuster drug in 2019.● Structured international organizations and revitalized teams, operations, and brand perceptions to navigate industry changes and exceed performance goals for Bayer AG.● Negotiated deals, such as the agreement between Bayer and Orion Corporation; managed partnerships including Genzyme, Orion Corporation, and Regeneron Pharmaceuticals.● Launched billion-dollar products, including Eylea®, Stivarga®, and Xofigo®, and positioned mature brands such as Betaferon®, Kogenate®, and Nexavar® for heightened success.I attribute my success to the determination, expertise, and hard work of my teams. It is a true privilege to work together in the quest to develop patient-centric organizations that deliver life-changing medications globally.

Robert was appointed President and Chief Executive Officer of Cytokinetics in January 2007 and has been a member of our Board of Directors since then. Previously, he served as Cytokinetics’ President and held other senior-level positions at the Company overseeing research and development, finance, corporate development, legal, commercial operations, and business development at various times since participating in the launch of Company operations in 1998. Prior to Cytokinetics, Robert held senior positions in business development and marketing at COR Therapeutics from 1991 to 1998. He also performed roles of increasing responsibility in sales, marketing, and other pharmaceutical business functions at Marion Laboratories and Syntex Corporation beginning in 1981. Robert has served on the faculty at the Center for BioEntrepreneurship at University of California, San Francisco, where he taught a corporate finance course to graduate students. He co-chaired the BIO Business Development Committee and is a frequent lecturer on matters of business development and finance in the biopharmaceutical industry. He served on the National Board of the American Committee of the Weizmann Institute of Science and established the Blum Family Venture Philanthropy Fund to propel basic science discoveries at the Institute with potential to benefit the Israeli life sciences economy. In addition, he established the Tikkun Olam Youth Science Prizes for Bay Area middle and high schools, designed to further science education and exploration in the spirit of repairing the world. Robert served on the Board of the Jewish Community Federation of San Francisco and founded and chaired its Business Leadership Council. He also served on the Boards of San Francisco’s Contemporary Jewish Museum and the Anti-Defamation League. Robert was named a Henry Crown Fellow of the Aspen Institute in recognition of his leadership in corporate and civic responsibilities. He is a member of the Aspen Global Leadership Network and has moderated seminars related to science, health, and technology at Aspen Action Forums. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School. Robert was a fan of mountain bluegrass music long before it was fashionable and has been known to carry a harmonica in his briefcase, much to the dismay of nearby hotel guests. He enjoys trying to keep up with his wife Dana and daughters, Brittany and Bridget, as well as his Bernese mountain dog, Baron, on long hikes in the Presidio.

Prior to joining Genocea,Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Chief Executive Officer and member of the board of XOMA (NASDAQ: XOMA). Joined XOMA in 2009 and was appointed to the CEO role in late 2016. In early 2017, Mr. Neal led XOMA through a dramatic strategic pivot taking the company from a traditional R&D heavy biotech company and transforming it to a successful royalty monetization and aggregation company. In the years prior to becoming CEO of XOMA, he was instrumental in leading the company’s licensing and business development activities focused on maximizing the value of XOMA’s foundational antibody IP and knowhow. In addition to his role at XOMA, Mr. Neal currently serves as a Director at Leading Biosciences, a clinical stage biotech company based in Carlsbad, CA. Mr. Neal has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Prior to XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos Inc., a leading bio-simulation company that acquired Iconix Biosciences, a privately held company where Mr. Neal was Chief Executive Officer. At Iconix, Mr. Neal established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs (now AbbVie), Eli Lilly and the U.S. Food and Drug Administration. From 1999-2002, he was Executive Vice President of Incyte Genomics, leading global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis, GSK and others. Earlier in his career, he was an executive with Monsanto Company in positions of increasing responsibility. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an MBA degree from Washington University in St. Louis, MO.

Skip Wagner is a President and Chief Executive Officer at BioReliance and is based in College Station, Texas.

Highly motivated senior executive with general management experience in both large multi-national companies and small private equity environments in the diagnostic, medical device, pharmaceutical and life science industries. Demonstrated performance excellence in multi-disciplinary leadership roles including operations, marketing, sales, strategic planning, acquisitions and integrations on domestic and international level. Excel at turning around underperforming businesses with a combination of strong business acumen, outstanding leadership, customer relationships, and superior commercial execution. Dynamic leader with ability to build high performing teams and cross functional collaboration, align and inspire organizations towards a clear vision, and execute for sustainable results.

Michael Reilly is a biotechnology commercialization professional working with emerging biotechnology companies, venture capital, and private equity firms on commercialization and business development. His focus is on shaping and maximizing the future value of medicines for patients and investors through thoughtful choices in the product development process. Michael has over 20 years of leadership experience in pharmaceuticals, devices, diganostics, and industrial biotechnology. His direct experience in developing and commercializing drugs spans pre-IND stage, clinical, launch, and patent expiration.